Oxford Cann Share News (OCTP)

Oxford Cannabinoid teams with iNGENu to test OCT130401 pain treatment

(Alliance News) - Oxford Cannabinoid Technologies Holdings PLC announced on Thursday that its subsidiary, OCT Victoria Pty Ltd, has entered an agreement with iNGENu CRO Pty Lt to conduct a study evaluating the safety of OCT130401.

IN BRIEF: Oxford Cannabinoid completes capital reorganisation

Oxford Cannabinoid Technologies Holdings PLC - Oxford, England-based pharmaceutical company developing prescription cannabinoid medicines - Says that its capital reorganisation is now complete.

IN BRIEF: Oxford Cannabinoid shares up on applying to admit new shares

Oxford Cannabinoid Technologies Holdings PLC - Oxford, England-based pharmaceutical company developing prescription cannabinoid medicines - Following the raising of GBP646,000 through the issue of 128.0 million new shares at a price of 0.5 pence each, as announced late last month, the company says it makes applications to the UK Financial Conduct Authority and London Stock Exchange to admit these shares to the Main Market in London. Expects the new shares to begin trading on Tuesday next week. Following admission, there will be 1.09 billion total Oxford Cannabinoid shares in issue.

IN BRIEF: Oxford Cannabinoid applies for new shares to be listed

Oxford Cannabinoid Technologies Holdings PLC - Oxford, England-based pharmaceutical company developing prescription cannabinoid medicines - Says application has been made to the Financial Conduct Authority and the London Stock Exchange Group PLC for the redenominated ordinary shares resulting from the capital reorganisation to be admitted to the Official List. This follows the approval of a capital reorganisation by shareholders in September 2023. Oxford Cannabinoid expects around 960.4 million shares will be admitted to trading and dealings will commence on the London Stock Exchange February 16.

UK shareholder meetings calendar - next 7 days

IN BRIEF: Oxford Cannabinoid agrees GBP565,000 loan notes deal

Oxford Cannabinoid Technologies Holdings PLC - Oxford, England-based pharmaceutical company developing prescription cannabinoid medicines - Enters convertible loan note agreement with Cantheon Capital LLC, as well as existing shareholders and directors, for up to GBP565,000. Cantheon, an investor in early- and mid-stage biotechnology companies, will provide GBP450,000. The total proceeds will be used to fund phase I trials of Oxford Cannabinoid's trigeminal neuralgia treatment OCT130401, expected to commence in the second quarter of 2024. Trigeminal neuralgia is a condition which affects a nerve inside the skull and can cause severe pain. Oxford Cannabinoid believes that the trigeminal neuralgia market has a value of around GBP1.8 billion.

Oxford Cannabinoid Technologies down after GBP1.2 million fundraise

(Alliance News) - Oxford Cannabinoid Technologies Holdings PLC on Tuesday announced narrowing losses and a new government tax credit, as shares fell following a fundraise of GBP1.2 million for its latest programme trials.

UK earnings, trading statements calendar - next 7 days

IN BRIEF: Oxford Cannabinoid stock goes high on Europe patent filing

Oxford Cannabinoid Technologies Holdings PLC - Oxford-based pharmaceutical company developing prescription cannabinoid medicines - Files European patent application in its own name directed to Programme 2. Application is directed to a composition containing Delta-9-tetrahydrocannabinol or THC, and Cannabidiol or CBD. Patent will give company exclusive rights to use, produce and sell this composition most likely for up to two decades, allowing it to recoup its Research & Development investment and gain a competitive market advantage. Notes however that grant process could take up to five years. Company expects to file multiple other Programme 2 applications this year, followed by an international patent application next year.

IN BRIEF: Kingsley Capital reduces stake in Oxford Cannabinoid

Oxford Cannabinoid Technologies Holdings PLC - Oxford-based pharmaceutical company developing prescription cannabinoid medicine - Kingsley Capital Partners LLP sells 54.9 million shares in the company, of which 20.5 million were acquired by Neil Mahapatra in his own name. Neil Mahapatra, the managing partner of KCP, controls the exercise of 100% of KCP's voting rights in OCT. Kingsley Capital Partners stake in Oxford Cannabinoid falls to 14.95% from 20.76%.

Oxford Cannabinoid completes Phase 1 study for lead asset OCT461201

(Alliance News) - Oxford Cannabinoid Technologies Holdings PLC on Tuesday said it has "successfully completed" the dosing of all the cohorts of its Phase 1 study for its lead pharmaceutical asset, OCT461201.

Oxford Cannabinoid issues final dose of lead pharmaceutical asset

(Alliance News) - Oxford Cannabinoid Technologies Holdings PLC on Monday said the final dose of its lead pharmaceutical drug compound, OCT461201, has been successfully administered.

UK shareholder meetings calendar - next 7 days

EARNINGS SUMMARY: Gulf Keystone swings to loss; Gulf Marine optimistic

(Alliance News) - The following is a round-up of earnings of London-listed companies, issued on Thursday and not separately reported by Alliance News:

SMALL-CAP WINNERS & LOSERS: PPHE Hotels rises on swing to profit

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Thursday.